Rio Rancho, NM โ April 20, 2026 โ Q Biotech Corp, a leading innovator in life science technologies, today announced the appointment of David Briggs, PhD, as Strategic Advisor to the company. In this role, Dr. Briggs will support the companyโs commercial growth strategy following the development of its proprietary protein separation technology, Inceptumโข.
Most purification workflows arenโt difficult because of the science.
Most purification workflows donโt fail. ๐ป๐๐๐ ๐๐๐๐ ๐๐๐ ๐๐๐๐๐๐๐๐๐๐๐ .
With disposable fluid paths and streamlined workflows, Inceptum enables faster transitions from one run to the next โ without the need for extensive cleaning or system preparation.
In protein purification workflows, results are only as valuable as the confidence behind them.
Selecting a new purification system is a decision most laboratories prefer to evaluate carefully. Thatโs why Q Biotech offers labs the opportunity to evaluate the Inceptumโข purification system directly on their own bench.
In many labs, purification systems look similar on paper. But the day-to-day experience tells a different story.
In research environments, instrument performance is often measured in run time, resolution, and yield.
In life science R&D, purification speed is often measured in minutes โ but scientific progress is measured in how quickly teams can iterate between experiments.
At Q Biotech, weโve spent years refining how chromatography runs happen โ focusing on speed, simplicity, and reproducibility